Acceptability and Concordance of Self- Versus Clinician-Sampling for HPV Testing among Rural South Indian Women

Purnima Madhivanan1,2,3*, Holly Nishimura4, Kavitha Ravi2, Benjamin Pope5, Makella Coudray6, Anjali Arun2, Karl Krupp1,2, Poornima Jaykrishna2, Vijaya Srinivas2

Abstract

Background: Despite being largely preventable, HPV-related cervical cancers continues to be the second highest cause of cancer deaths among Indian women. HPV testing using self-sampled samples may offer an opportunity to expand cervical cancer screening in India where there is currently a shortage of providers and facilities for cervical cancer screening. The study examines acceptability and concordance of self vs. clinician collected samples for HPV-related cervical cancer screening among rural South Indian women. Methods: Between May and August 2017, eight mobile screening clinics were conducted among 120 eligible women in rural villages in Mysore District, India. Women over the age of 30 underwent informed consent process and then self-sampled a sample for cervicovaginal HPV DNA testing. Next, the women underwent clinical exam where the clinician collected a cervicovaginal HPV DNA sample. Following the clinical exam, all participants answered an interviewer-administered questionnaire to assess their history of cervical cancer screening and acceptability of self- and clinician-sampling methods. To assess diagnostic accuracy, concordance of self- and clinician-sampled HPV DNA specimens was calculated in addition to five measures of acceptability (feeling of caring, privacy, embarrassment, genital discomfort, and genital pain). Results: Study participants had a median age 39 years, about four-in-ten (41.7%) had a secondary education or above, the vast majority (87.5%) were married and only 3.4% reported having screened for cervical cancer. For all measures of participant acceptability, self-sampling was rated significantly higher than clinician-sampling. Cohen’s kappa was 0.73 (95% CI: 0.34, 1.00), indicating substantial agreement between self- and clinician-sampling. Conclusion: This study demonstrates that HPV self-sampling for cervical cancer screening is feasible and acceptable in a community setting among South Indian rural women. Concordance between self-sampling and clinician-sampling was adequate for screening in community settings.

Keywords: Screening cervical cancer- self-collection- self-sampling- India

Asian Pac J Cancer Prev; 22 (3), 971-976

Introduction

Cervical cancer is the fourth most common cancer in women worldwide, and the seventh overall, with an estimated 570,000 incident cases per year with 311,000 women dying from the disease (Ferlay et al., 2015; World Health Organization, 2020). Approximately 84% of cases and 88% of cervical cancer deaths occur in low- and middle-income countries (Randall and Ghebre, 2016; Arbyn et al., 2020). High income countries have been effective in reducing cervical cancer incidence and mortality due to population-based cytologic screening programs (Kamangar et al., 2006; Ferlay et al., 2015; Beddoe, 2019). Cytology-based screening, conducted as part of a pelvic examination, is a method of detecting pre-invasive neoplasia (also known as pre-cancerous lesions). Detection and treatment of neoplasia at the pre-invasive stage can prevent lesions from becoming cancerous. Advances in cytology-based screening, however, have not translated to less developed regions including countries in Africa, South and Southeast Asia, and parts of Latin America where cervical cancer is the second most common cancer.

To address many of the barriers to cervical cancer...
screening, the World Health Organization recommends low-cost, culturally-acceptable alternatives to cytology such as Human Papillomavirus (HPV) DNA testing (WHO). Persistent HPV infection is associated with the vast majority of cervical cancer cases (WHO). Tests for HPV DNA are easily reproducible and have higher sensitivity for detecting high-grade cervical intraepithelial neoplasia than cytological tests (WHO; Sankaranarayanan et al., 2011; Bansil et al., 2014; Sankaranarayanan, 2014; Racey and Gesink, 2015). A meta-analysis found an overall sensitivity of 80-95% for HPV testing compared to 60-80% for cytologic testing, and an overall specificity of 50-70% for HPV testing compared to 85-95% for cytologic testing (Sahasrabuddhe et al., 2012). Unlike cytologic testing, HPV testing does not require retesting or multiple visits from the patient. HPV testing also offers an option for self-sampling where cytologic testing does not.

Due to the physical and psychological discomfort associated with the pelvic exam necessary for cytologic testing, self-sampling may be an acceptable alternative. Furthermore, Indian women continue to be hesitant and shy about undergoing a pelvic exam culturally. The self-sampling method addresses structural issues to resource constraints, lack of staff, and space to provide screening. A recent systematic review of 37 self-collection studies from 24 countries found overall high acceptability (Nelson et al., 2017). A self-sampling option may be appealing to women that would otherwise not screen.

The Indian ministry of Health and Family Welfare has been piloting cervical cancer screening programs in select states since November 2016 (Busu et al., 2019; Kedar et al., 2019). India with the world’s second largest population, also experiences a large proportion (27%) of the world’s cervical cancer deaths annually (Sankaranarayanan, 2014). Each year 96,922 women are diagnosed with cervical cancer and 60,078 die from the disease (Sankaranarayanan et al., 2011; National Institute of Cancer Prevention and Research and Indian Council of Medical Research, 2018). The screening program required mandatory oral, breast, and cervical cancer screening for people over the age of 30 in 100 selected districts of India (Bagcchi, 2016). While preliminary data regarding the overall impact of cancer screening program is not available, three hospital based studies showed promising results (Sowjanya et al., 2005; Mehtal, 2017; Kuriakose et al., 2020). If the nation-wide screening program is to be successful in the culturally and economically diverse regions of India, feasibility and acceptability of different screening methods must be identified and addressed.

This study was conducted in a community-based setting in rural communities in the state of Karnataka among asymptomatic women attending a mobile cervical cancer screening program. The objective was to assess the feasibility and acceptability of self-sampling for HPV testing as compared to clinician-collected sample.

Materials and Methods

Study Sample/Population

This was a cross-sectional study that collected data between May and August 2018. Two-hundred participants were recruited in order to obtain a sample size of 120 as a convenience sample from the community. Inclusion criteria for participation was being 30 years or older, who have not undergone cervical cancer screening within the last three years, and having the capacity to undergo informed consent process. Women who had had a hysterectomy, currently menstruating, pregnant or had been diagnosed with cervical cancer were excluded from the study. The women who were menstruating were invited to enroll after menstruation.

Ethical approvals

Only women who were able to give informed consent were recruited to participate in the study. The study research protocol was reviewed and approved by the institutional ethics committees of Public Health Research Institute of India and University of California, Berkeley.

Recruitment

The study was conducted at the Public Health Research Institute of India (PHRII) mobile cervical cancer screening program in Mysore, Karnataka, India. A study staff member invited women in the waiting area awaiting a pelvic exam as part of the standard of care for cervical cancer screening, to participate in the study. The mobile clinics were set up in eight rural villages of Mysore District in cooperation with District surveillance officer who represents the District Health and Family Welfare Officer, Mysore.

Screening

Women who were eligible to participate were seen by a member of the research staff to obtain informed consent in Kannada, the predominant language spoken in the region. Participants then answered an interviewer administered brief questionnaire to collect socio-demographic, reproductive, and health data, as well as an assessment of knowledge regarding cervical cancer. After the screening was completed, they completed a short interviewer-administered survey on acceptability of the collection method.

Procedure

After the screening questionnaire was completed by the study staff member, the participant was asked to self-collect a vaginal swab in the privacy of their homes or in a private space near the mobile clinic. Women were given verbal and pictorial instructions prior to sample-collection about the use of a cervical brush, which was then swirled and stored in the PreservCyt Solution. Briefly, the woman was instructed to insert the swab two inches into her vagina, swirl three times along the upper vaginal wall, then to remove and place the swab into the provided collection tube and return to the research staff. Swab insertion and removal was not witnessed by the research staff member. The cervicovaginal sample was collected using a broom-type collection device (Digene HC2 NA Collection Device) and then placed in a 1ml of specimen transport medium (STM) containing PreservCyt solution to prevent drying of the sample. At the time of
receipt, the study interviewer verified if the swab was completely submerged into the solution and the collection bottle was closed correctly.

As part of the standard of care for cervical cancer screening, a clinician performed a pelvic examination. Lubricant was not applied to the speculum prior to insertion. After speculum placement, the cervical os was visualized and a cotton-tipped swab was used to remove any excess secretions. An endocervical specimen was collected by inserting the brush-like collection device into the cervical os and rotating five times. This was placed in the collection device which was then sent to PHRII laboratory by maintaining cold/refrigerated condition for further testing for HPV. After the completion of the examination, the research interviewer administered an acceptability questionnaire about the woman’s experiences with the pelvic exam and self-sampling processes. The questionnaire was a Likert scale, that ranged from 1(least favorable) to 5(most favorable), to evaluate experiences related to perception of care, comfort, privacy, embarrassment, and pain for both collection methods individually. Measures used in the acceptability questionnaire have been previously used in other HPV self-sampling studies. The questionnaire also assessed difficulties encountered during self-sampling and questions regarding the ability to perform the self-sampling.

Testing

The Digene HC2 NA Collection Device was used for self- and clinician-sampling. Both samples were transported to and tested at the PHRII laboratory using the digene Hybrid Capture 2 HPV DNA Test, on a Qiagen platform which detects 13 high-risk HPV types (16/18/31/33/35/39/45/51/52/56/58/59/68). Results were reported as positive or negative for high and low risk types.

Data Analysis

Summary statistics were generated for demographic variables and clinical characteristics. Additionally, summary statistics were tabulated for preferences for cervical cancer screening, including gender preference of the provider, collection type preference (physician or self), whether the respondents would test with self-sampling again, and whether they would recommend self-sampling to a friend. A 2-by-2 table was generated to compare self-sampling versus clinician-sampled specimens. From this table, performance measures and their associated 95% confidence intervals were generated, including sensitivity and specificity, predictive values positive and negative, and the proportion of concordant pairs and the proportion of concordant pairs among those pairs for which the clinician-sampled sample was HPV DNA testing. Any indeterminate index test or reference standard results were treated as missing. Missing data were excluded from analyses, that is, no imputation was performed.

Acceptability measures included: how well cared for respondents felt; how well the respondents’ privacy was handled during the tests; the extent to which respondents felt embarrassed during the test; whether the test caused the respondents’ genital discomfort; and whether the test caused the respondents’ genital pain.

We used the following formula to determine the sample size for the study:

\[ 1.96 \sqrt{\frac{3s^2}{n}} = \text{desired confidence interval of LoA} \]

The formula suggested that a sample size of 100 would result in a confidence interval estimated to be 0.05. This was consistent with recommendations from McAlinden et al that sample sizes for agreement studies should include at least 100 subjects(McAlinden et al., 2011). We overrecruited by 20% to account for incomplete data and ‘indeterminate’ test results.

Data were compared using a paired t-test, or, as appropriate, the Wilcoxon signed-rank test. Cohen’s kappa, a measure of agreement between two raters, was also computed. For Cohen’s kappa, a value near zero represented agreement being due to random chance, 0.01-0.20 represented slight agreement; 0.21-0.40, fair agreement; 0.41-0.60, moderate agreement; 0.61-0.80, substantial agreement; and 0.81-1.00 almost perfect agreement. All tests were carried out using an α=0.05 significance level. Stata version 11.2 (StataCorp, College Station, TX) was used for all analyses except for Cohen’s Kappa and its associated confidence interval, for which the ckap command, part of the rel package in R version 3.6.2 (R Core Team 2019), was used.

Results

Sociodemographic characteristics of the study participants is in Table 1. Among the participants, the median age was 39 (IQR: 32-45), while the median monthly income was 5,000 INR (IQR: 3,000-10,000). The highest percentage of respondents (41.7%, n=50) had secondary or higher education, while the majority (n=113, 95.0%) were Hindu, married (87.5%, n=105), and never smokers (n=113, 94.2%). About three-fifths of respondents (57.1%) reported having never been screened for cervical cancer.

Overall prevalence of HPV DNA positivity in the clinician sampled endocervical swab samples was 12.6% (95%CI: 7.7, 19.9). The self-sampled vaginal swab, when compared to the gold standard of the clinician-sampled endocervical swab for HPV DNA testing, had a greater specificity (98.1%; 95% CI: 95.5, 100) than it did sensitivity (66.7%; 95% CI: 42.8, 90.6). The overall agreement between the two tests was 94.1% (95% CI: 88.1, 97.3). The Cohen’s kappa value was 0.735 (95% CI: 0.342, 1.0) (Table 2).

The vast majority (84.8%) of respondents preferred to have a provider of the same gender for their pelvic examinations, while about three-in-five (59.3%) preferred to self-sample for their HPV DNA test. All said that they would test with self-sampling method again and recommend self-sampling to a friend (Table 3). For each of the five measures of acceptability of self-sampling versus clinician-sampling, self-sampling was significantly more favorable than was physician collection (all p-values were less than 0.05).

Asian Pacific Journal of Cancer Prevention, Vol 22
well cared for the participants felt (mean of 3.57 for self-sampled versus 3.46 for clinician-sampled), while the largest difference was in whether the test caused genital pain (mean of 3.42 for self-sampling versus 2.85 for clinician-collected) (Table 4).

Discussion

This study was designed to inform the feasibility and acceptability for conducting community based cervical cancer screening programs using mobile clinics in rural communities in India. The study has reiterated that self-sampling of vaginal samples was feasible and acceptable to women living in rural India. In fact, they preferred self-sampling and were comfortable with the process. By using self-collected samples to rule out HPV infection, it is possible to reduce missed opportunities for screening in rural India.

Additional considerations for the feasibility of large-scale HPV self-sampling campaigns concern accuracy of results of the self-sampling process. This study found comparable performance and accuracy of self-sampling for detection of high-risk HPV DNA. There have been several studies comparing HPV screening results from self-collected and clinician-collected specimens in low- and middle-income countries with all demonstrating high levels of agreement (Bhatla et al., 2009; Quincy et al., 2012; Verma and Khanna, 2013; Nilyanimit et al., 2014; Rosenbaum et al., 2014; Adamson et al., 2015; Ma’som et al., 2016).

Table 1. Demographic and Clinical Characteristics

| Characteristics                              | n (%) or median (IQR) |
|----------------------------------------------|-----------------------|
| Demographic Characteristics                  |                       |
| Age (years)                                  | 39 [32-45]            |
| Monthly income (INR)                         | 5000 [3000-10,000]    |
| Education                                    |                       |
| None                                         | 29 (24.2)             |
| Primary (1-4)                                | 14 (11.7)             |
| Middle (5-7)                                 | 25 (20.8)             |
| Secondary or above (8 or above)              | 50 (41.7)             |
| Religion                                     |                       |
| Hindu                                        | 113 (94.2)            |
| Muslim                                       | 6 (5.0)               |
| Marital status                               |                       |
| Married                                      | 105 (87.5)            |
| Widowed                                      | 14 (11.7)             |
| Ever screened for cervical cancer            |                       |
| No                                           | 64 (53.8)             |
| Yes                                          | 4 (3.4)               |
| Don’t Know                                   | 51 (42.9)             |

Table 2a. Screening Results among Women Attending Mobile Cervical Cancer Screening in Mysore, India (N=119)

| Measure                                      | n (%)                  |
|----------------------------------------------|------------------------|
| Self-Sampled cervicovaginal HPV DNA          |                        |
| Positive                                     | 12 (10.1)              |
| Negative                                     | 107 (89.9)             |
| Clinician-sampled cervicovaginal HPV DNA     |                        |
| Positive                                     | 15 (12.6)              |
| Negative                                     | 104 (87.4)             |

Table 2b. Accuracy and Test Concordance Comparing Self- and Clinician-Sampled HPV DNA among Women Attending Mobile Cervical Cancer Screening in Rural Mysore, India (N=119)

| Measure                                      | Estimate | 95% CI |
|----------------------------------------------|----------|--------|
| Sensitivity                                  | 66.7     | 42.8, 90.6 |
| Specificity                                  | 98.1     | 95.5, 100.0 |
| Positive predictive value                    | 83.3     | 62.2, 100.0 |
| Negative predictive value                    | 95.3     | 91.3, 99.3 |
| κ-statistic                                  | 73.5     | 34.2, 100.0 |
| Total agreement                              | 94.1     | 88.1, 97.3 |
| HPV positive agreement                       | 66.7     | 41.5, 85.0 |

Table 3. Cervical Cancer Screening Examination Preferences (n=118)

| Measure                                      | n (%)    |
|----------------------------------------------|----------|
| Gender preference for provider               |          |
| Male                                         | 1 (0.9)  |
| Female                                       | 100 (84.8) |
| No preference                               | 17 (14.4) |
| Collection type preference for HPV DNA test  |          |
| Self-sampling                               | 70 (59.3) |
| Clinician-sampling                          | 33 (28.0) |
| No preference                               | 15 (12.7) |
| Test with self-sampling again (n=117)        |          |
| No                                          | 0 (0%)   |
| Yes                                         | 117 (100%) |
| Recommend self-sampling to a friend          |          |
| No                                          | 0 (0%)   |
| Yes                                         | 118 (100%) |

Table 4. Acceptability of Self-Sampling Compared to Clinician-Sampling for HPV DNA Testing (N=118)

| Acceptability Measure                        | Self-sampling Mean (SD) | Physician-sampling Mean (SD) | p-value |
|----------------------------------------------|-------------------------|-----------------------------|---------|
| How well cared for did you feel?             | 3.57 (0.70)             | 3.46 (0.63)                 | 0.005   |
| How well was your privacy handled during the test? | 3.61 (0.66)             | 3.47 (0.59)                 | <0.001  |
| Did you feel embarrassed?                   | 3.47 (0.68)             | 3.25 (0.63)                 | <0.001  |
| Did the test cause you any genital discomfort? | 3.47 (0.64)             | 3.00 (0.94)                 | <0.001  |
| Did the test cause you any genital pain?     | 3.42 (0.67)             | 2.85 (1.06)                 | <0.001  |

*Range from 1 to 5, 1, least favorable; 5, most favorable
al., 2016). A review and meta-analysis of 21 studies did not detect statistically significant difference in sensitivity of self-collected specimens compared to clinician-collected specimens. The authors suggested a pooled analysis of sensitivity data to detect whether sampling methods yielded statistically different sensitivities. The majority of studies in the review reported similar specificity for both sampling methods (Snijders et al., 2013). Clinically, the data suggested that self-sampling of HPV specimens was a viable alternative to clinician-sampling.

**Interpretation in light of other evidence**

Consistent with previous studies comparing self-sampled to clinician-collected specimens, we found that self-sampled HPV specimens have a great potential to be used in community-based, screening programs. A review of nine studies found that participation in a cervical cancer screening program increased from 8.7% to 39% when self-sampling was offered as a screening option (Snijders et al., 2013). Overall, current data suggest that a self-sampling option can increase participation in cervical cancer programs in India, and other low- and middle-income countries. While there have been reports of their successful use in Africa, Latin America and in developed countries, there is limited data of their use in India (Lazcano-Ponce et al., 2011; Rees et al., 2018).

This is also one of the few studies that examined the usefulness of self-sampled swabs for cervical cancer screening in rural India (A Peedicayil et al., 2016; Adsul et al., 2019). Furthermore, the laboratory assessments of both modes of sample collection revealed high concordance when comparing specimens collected by self-sampling and clinician-collected swabs. Thus, self-sampled swabs were acceptable to a substantial group of rural women and were reliable in terms of the detection of HPV DNA making them one of the preferred methods to be used in population based surveillance of reproductive cancers such as cervical cancer.

**Limitations**

This study should be considered in light of its limitations. First, since this was a pilot study to evaluate the interest and acceptability of using self-sampling before rolling out the large screening program, the sample size was small. It is likely that women may have self-selected to participate in the study and hence the findings may not be generalizable. Second, it is possible that there might be information bias as the acceptability information may be influenced by the fact that the women were asked to respond to the survey by an interviewer. Despite these limitations, this was one of the first studies to examine the feasibility and acceptability of using self-sampling techniques in a community based setting in a rural area of India. We used standardized tests to screen for HPV DNA and all study staff were trained to administer the surveys in a non-judgmental manner.

Based on the findings from this study, PHRII has used self-collected swabs as one of the main methods for specimen collection in all their subsequent community studies of cervical cancer screening in rural Mysore, India. This study demonstrated that self-sampled swabs were preferred by a large number of women, especially when the instructions on collection were provided in a user friendly, non-judgmental manner.

In conclusion, this study demonstrates that HPV self-sampling for cervical cancer screening is feasible and acceptable in a community setting among South Indian rural women. Concordance between self-sampling and clinician-sampling was adequate for screening in community settings raising the possibility that large scale screening programs could reduce the burden of cervical cancer cases and deaths in India.

**Author Contribution Statement**

Dr. Madhivanan had full access to all data in the study and takes responsibility for the integrity of the data and accuracy of the data analysis. All authors accept responsibility for the paper as published. Study concept and design: Nishimura, Krupp, Ravi, Jaykrishna, Madhivanan, Srinivas, Arun. Acquisition of data: Nishimura, Ravi, Krupp, Jaykrishna, Srinivas, Arun. Analysis and interpretation of data: Nishimura, Pope, Coudray, Madhivanan, Jaykrishna, Krupp. Drafting of the manuscript: Madhivanan, Pope, Krupp, Ravi, Coudray, Nishimura. Critical revision of the manuscript for important intellectual content: All authors.

**Acknowledgements**

Research reported in this publication was supported by the National Institutes for Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The Public Health Research Institute of India received the HPV testing equipment in kind from Qiagen for the purpose of this research study. The authors wish to thank all the staff at PHRII and women who participated in the study.

**Funding Source**

HN was funded by the NIH National Center on Minority Health & Health Disparities (T37 MD003406), PM and KK were partially funded by NIH Fogarty International Center; National Heart, Lung, and Blood Institute; and National Institute of Neurological Disorders and Stroke (D43 TW010540). PM, MC were partly funded by NIH National Institute of Allergy and Infectious Diseases (R15 AI28714-01). The funders had no role in the study design, data collection, management, analysis, or interpretation of the data, and preparation, review, or approval of the manuscript.

**Details of Ethics Approval**

The study was reviewed and approved by the Institutional Review Boards at University of California, Berkeley (Protocol #2017-03-9670; Dated 4th April 2017) and Public Health Research Institute of India, Mysore (Protocol #2017-04-01-36; Dated 1st April 2017).

**Competing Interests**

The authors declare that they have no competing interests.
interests.

References

A Peedicayil, P Abraham, J Prasad, et al (2016). Community prevalence of human papillomavirus by self-collected samples in South India. Indian J Gynecol Oncol, 14, 16.

Adamson PC, Huchko MJ, Moss AM, et al (2015). Acceptability and accuracy of cervical cancer screening using a self-collected tampon for HPV messenger-RNA testing among HIV-infected women in South Africa. PloS One, 10, e0137299.

Adusl P, Srinivas V, Gowda S, et al (2019). A community-based, cross-sectional study of hrHPV DNA self-sampling-based cervical cancer screening in rural Karnataka, India. Int J Gynaecol Obstet, 146, 170-6.

Arbyn M, Weiderpass E, Bruni L, et al (2020). Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health, 8, e191-e203.

Bagcchi S (2016). India launches plan for national cancer screening programme. BMJ, 355, i5574.

Bansil P, Wittet S, Lim JL, et al (2014). Acceptability of self-collection sampling for HPV-DNA testing in low-resource settings: a mixed methods approach. BMC Public Health, 14, 596.

Basu P, Mahajan M, Patira N, et al (2019). A pilot study to evaluate home-based screening for the common non-communicable diseases by a dedicated cadre of community health workers in a rural setting in India. BMC Public Health, 19, 14.

Beddoe AM (2019). Elimination of cervical cancer: challenges for developing countries. Ecancermedicalscience, 13, 975.

Bhatla N, Dar L, Patro AR, et al (2009). Can human papillomavirus DNA testing of self-collected vaginal samples compare with physician-collected cervical samples and cytology for cervical cancer screening in developing countries? Cancer Epidemiol, 33, 446-50.

Ferlay J, Soerjomataram I, Dikshit R, et al (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 136, E359-86.

Kamangar F, Dores GM, Anderson WF (2006). Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol, 24, 2137-50.

Kedar A, Kannan R, Mehrrota R, Hariprasad R (2019). Implementation of population-based cancer screening program in a pilot study from India: Views from Health Personnel. Indian J Community Med, 44, 68-70.

Kuriakose S, Sabeena S, Binesh D, et al (2020). Diagnostic accuracy of self-collected vaginal samples for HPV DNA detection in women from South India. Int J Gynaecol Obstet, 149, 219-24.

Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A, et al (2011). Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet, 378, 1868-73.

Ma’som M, Bhoo-Pathy N, Nasir NH, et al (2016). Attitudes and factors affecting acceptability of self-administered cervicovaginal sampling for human papillomavirus (HPV) genotyping as an alternative to Pap testing among multiethnic Malaysian women. BMJ Open, 6, e011022.

McAlinden C, Khadka J, Pesudovs K (2011). Statistical methods for conducting agreement (comparison of clinical tests) and precision (repeatability or reproducibility) studies in optometry and ophthalmology. Ophthalmic Physiol Opt, 31, 330-8.

National Institute of Cancer Prevention and Research, Indian Council of Medical Research (2018). Globocan 2018: India Factsheet. http://cancerindia.org.in/globocan-2018-india-factsheet/.

Nelson EJ, Maynard BR, Loux T, et al (2017). The acceptability of self-sampled screening for HPV DNA: a systematic review and meta-analysis. Sex Transm Infect, 93, 56-61.

Niliyanmit P, Wanlapakorn N, Niruthiklard S, et al (2014). Comparison of detection sensitivity for human papillomavirus between self-collected vaginal swabs and physician-collected cervical swabs by electrochemical DNA chip. Asian Pac J Cancer Prev, 15, 10809-12.

Quincy BL, Turbow DJ, Dabinett LN (2012). Acceptability of self-collected human papillomavirus specimens as a primary screen for cervical cancer. J Obstet Gynaecol Res, 38, 87-91.

Racey CS, Gesink DC (2015). Barriers and facilitators to cervical cancer screening among women in rural Ontario, Canada: The Role of Self-Collected HPV Testing. J Rural Health, 32, 136-45.

Randall TC, Ghebre R (2016). Challenges in prevention and care delivery for women with cervical cancer in Sub-Saharan Africa. Front Oncol, 6, 160.

Rees I, Jones D, Chen H, Macleod U (2018). Interventions to improve the uptake of cervical cancer screening among lower socioeconomic groups: A systematic review. Prev Med, 111, 323-35.

Rosenbaum AJ, Gage JC, Alfaro KM, et al (2014). Acceptability of self-collected versus provider-collected sampling for HPV DNA testing among women in rural El Salvador. Int J Gynaecol Obstet, 126, 156-60.

Sahasrabuddhe VV, Parham GP, Mwanahamuntu MH, Vermund SH (2012). Cervical cancer prevention in low-and middle-income countries: feasible, affordable, essential. Cancer Prev Res, 5, 11-7.

Sankaranarayanan R (2014). Screening for cancer in low-and middle-income countries. Ann Global Health, 80, 412-7.

Sankaranarayanan R, Swaminathan R, Jayant K, Brenner H (2011). An overview of cancer survival in Africa, Asia, the Caribbean and Central America: the case for investment in cancer health services. IARC Sci Publ, 162, 257-91.

Snijders PJ, Verhoef VM, Arbyn M, et al (2013). High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int J Cancer, 132, 2223-36.

Sowjanya AP, Jain M, Poli UR, et al (2005). Prevalence and distribution of high-risk human papilloma virus (HPV) types in invasive squamous cell carcinoma of the cervix and in normal women in Andhra Pradesh, India. BMC Infect Dis, 5, 116.

Verma R, Khanna P (2013). Human papilloma virus vaccines Need to be introduced in India. Human Vaccines Immunotherapeutics, 9, 97-9.

WHO Guidelines for screening and treatment of precancerous lesions for cervical cancer prevention: supplemental material: GRADE evidence-to-recommendation tables and evidence profiles for each recommendation, 2013. Available: https://www.who.int/reproductivehealth/publications/cancers/screening_and_treatment_of_precancerous_lesions/en/.

World Health Organization (2020). Cervical Cancer. https://www.who.int/health-topics/cervical-cancer#tab=tab_1.

This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.